section name header

Pronunciation

vay-soe-PRESS-in

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: antidiuretic hormones, vasopressors

Indications

High Alert


Unlabeled Use:

Action

  • Alters the permeability of the renal collecting ducts, allowing reabsorption of water.
  • Directly stimulates musculature of GI tract.
  • In high doses acts as a nonadrenergic peripheral vasoconstrictor.
Therapeutic effects:
  • Decreased urine output and increased urine osmolality in diabetes insipidus.
  • Increased BP

Pharmacokinetics

Absorption: IM absorption may be unpredictable. IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Rapidly degraded by the liver and kidneys; <5% excreted unchanged by the kidneys.

Half-Life: <10 min.

Time/Action Profile

(antidiuretic effect)

ROUTEONSETPEAKDURATION
IM, SUBQunknownunknown2–8 hr
IVunknownunknown30–60 min





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, chest pain, MI

Derm: paleness, perioral blanching, sweating

Endo: diabetes insipidus

F and E: water intoxication (higher doses)

GI: abdominal cramps, belching, diarrhea, flatulence, heartburn, nausea, vomiting

Neuro: "pounding" sensation in head, dizziness, trembling

Misc: allergic reactions, fever

Interactions

Drug-drug:

Route/Dosage

Diabetes Insipidus

Vasodilatory Shock

GI Hemorrhage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Pitressin, Vasostrict